[
    "{\"step_by_step_thinking\": \"Burkholderia cepacia is known to be inherently resistant to many antibiotics, making treatment challenging. However, there are certain antibiotics that have shown activity against Burkholderia cepacia. To determine the drug of choice for Burkholderia cepacia pneumonia, we need to consider the available treatment options and their effectiveness against this pathogen. Let's analyze the options:\\n\\nA. Aminoglycoside and colistin: Aminoglycosides have limited activity against Burkholderia cepacia, and colistin is generally reserved for multidrug-resistant infections. This combination may not be the most effective choice.\\n\\nB. Carbapenems with 3rd generation cephalosporins: Carbapenems, such as meropenem, have shown good activity against Burkholderia cepacia. However, the addition of a 3rd generation cephalosporin may not provide significant additional benefit.\\n\\nC. Tigecycline and cefepime: Tigecycline has demonstrated activity against Burkholderia cepacia, but cefepime alone may not be the most effective choice.\\n\\nD. Cotrimoxazole with 3rd generation cephalosporins: Cotrimoxazole (trimethoprim/sulfamethoxazole) is considered the drug of choice for Burkholderia cepacia infections. It has shown good activity against this pathogen and is often used as the first-line treatment.\\n\\nBased on the available options, the most appropriate choice for the treatment of Burkholderia cepacia pneumonia would be D. Cotrimoxazole with 3rd generation cephalosporins.\", \"answer_choice\": \"D\"}"
]